Innate Pharma reported better-than-expected earnings for Q1 2026. EPS came in at -0.1522, beating the forecast of -0.1616 by 5.82%. Revenue reached EUR 3.04 million, exceeding the EUR 2.68 million forecast by 13.43%.
Pre-market trading saw a 59.56% surge in stock price from EUR 1.36 to EUR 2.17, reflecting investor confidence in the company's strategic direction and financial performance.
The company is pursuing non-dilutive financing options for the lacutamab Phase III trial. Partnerships with AstraZeneca are progressing well, with monalizumab and IPH5201 showing strong potential.
